Profile data is unavailable for this security.
About the company
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
- Revenue in USD (TTM)0.00
- Net income in USD-191.34m
- Incorporated2015
- Employees108.00
- LocationPharvaris NVEmmy Noetherweg 2LEIDEN 2333 BKNetherlandsNLD
- Phone+31 712036410
- Websitehttps://pharvaris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.68bn | 123.00 | -- | 5.06 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.68bn | 60.00 | -- | 6.43 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 1.68bn | 14.00 | -- | 38.01 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 54.03m | -412.78m | 1.71bn | 539.00 | -- | 1.43 | -- | 31.67 | -7.12 | -7.12 | 0.932 | 20.41 | 0.0365 | 0.2096 | 7.36 | 100,237.50 | -27.89 | -10.70 | -29.52 | -11.34 | 88.26 | -- | -764.01 | -516.35 | 11.06 | -- | 0.00 | -- | 48.03 | -- | -161.27 | -- | -21.96 | -- |
| Definium Therapeutics Inc | 0.00 | -183.79m | 1.71bn | 105.00 | -- | 5.11 | -- | -- | -2.06 | -2.06 | 0.00 | 3.36 | 0.00 | -- | -- | 0.00 | -49.52 | -52.67 | -57.73 | -60.64 | -- | -- | -- | -- | -- | -- | 0.1088 | -- | -- | -- | -69.12 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.74bn | 60.00 | -- | 6.18 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.74bn | 263.00 | -- | 5.51 | -- | 12.97 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.75bn | 192.00 | -- | 3.00 | -- | 113.94 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.75bn | 65.00 | -- | 3.67 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Pharvaris NV | 0.00 | -191.34m | 1.79bn | 108.00 | -- | 4.98 | -- | -- | -3.41 | -3.41 | 0.00 | 5.62 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.81bn | 5.00 | -- | 5.98 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Intellia Therapeutics Inc | 67.67m | -412.69m | 1.82bn | 377.00 | -- | 2.67 | -- | 26.95 | -3.83 | -3.83 | 0.6246 | 5.77 | 0.0666 | -- | 7.53 | 179,498.70 | -40.60 | -35.53 | -45.39 | -39.16 | -- | -- | -609.85 | -872.47 | -- | -- | 0.00 | -- | 16.92 | 3.13 | 20.49 | -- | -20.63 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.87bn | 61.00 | -- | 15.79 | -- | 29.80 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.89bn | 122.00 | -- | 5.36 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Pharvaris NV's reporting currency: US Dollar USD
29.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 6.40m | 9.99% |
| Viking Global Investors LPas of 31 Dec 2025 | 3.65m | 5.70% |
| Commodore Capital LPas of 31 Dec 2025 | 1.89m | 2.95% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 1.83m | 2.85% |
| Saturn V Capital Management LPas of 31 Dec 2025 | 1.14m | 1.78% |
| Cormorant Asset Management LPas of 31 Dec 2025 | 1.08m | 1.69% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 941.61k | 1.47% |
| Point72 Asset Management LPas of 31 Dec 2025 | 711.63k | 1.11% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 702.05k | 1.10% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 671.47k | 1.05% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
